Animal models of autoimmune liver diseases

Liver Immunology: Principles and Practice

Volumn , Issue , 2007, Pages 293-306

  Biburger, Markus ^a   Tiegs, Gisa ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78651351613     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-518-3_24     Document Type: Chapter

References (125)

1. Bayer EM, Schramm C, Kanzler S, Lohse AW. [Autoimmune liver disease: Diagnosis and therapy] Z Gastroenterol 2004; 42:19-30
2. Boberg KM, Aadland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998; 33:99-103
3. McFarlane IG. Pathogenesis of autoimmune hepatitis. Biomed Pharmacother 1999; 53:255-263
4. Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol 2000; 32:181-197
5. Manns MP, Strassburg CP. Autoimmune hepatitis: Clinical challenges. Gastroenterology 2001; 120:1502-1517
6. Löhr H, Treichel U, Poralla T, et al. The human hepatic asialoglycoprotein receptor is a target antigen for liver-infiltrating T cells in autoimmune chronic active hepatitis and primary biliary cirrhosis. Hepatology 1990; 12:1314-1320
7. Treichel U, McFarlane BM, Seki T, et al. Demographics of antiasialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology 1994; 107:799-804
8. Hashimoto E, Lindor KD, Homburger HA, et al. Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo Clin Proc 1993; 68: 1049-1055
9. Löhr HF, Schlaak JF, Lohse AW, et alLKM-specific . Autoreactive CD4 and anticlonotypic T-cell responses in LKM-1 antibody-positive autoimmune hepatitis. Hepatology 1996; 24:1416-1421
10. Lohse AW, Kogel M, Meyer zum Buschenfelde KH. Evidence for spontaneous immunosuppression in autoimmune hepatitis. Hepatology 1995; 22:381-388
11. Gordon MA, Oppenheim E, Camp NJ, et al. Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region. J Hepatol 1999; 31:242-247
12. Agarwal K, Jones DE, Daly AK, et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 2000; 32:538-541
13. Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis. Hepatology 1989; 10:430-436
14. Meyer zum Buschenfelde KH, Hopf U. Studies on the pathogenesis of experimental chronic active hepatitis in rabbits. I. Induction of the disease and protective effect of allogeneic liver specific proteins. Br J Exp Pathol 1974; 55:498-508
15. Hopf U, Meyer zum Buschenfelde KH. Studies on the pathogenesis of experimental chronic active hepatitis in rabbits. II. Demonstration of immunoglobulin on isolated hepatocytes. Br J Exp Pathol 1974; 55:509-513
16. Kuriki J, Murakami H, Kakumu S, et al. Experimental autoimmune hepatitis in mice after immunization with syngeneic liver proteins together with the polysaccharide of Klebsiella pneumoniae. Gastroenterology 1983; 84:596-603
17. Lohse AW, Manns M, Dienes HP, et al. Experimental autoimmune hepatitis: Disease induction, time course and T-cell reactivity. Hepatology 1990; 11:24-30
18. Lohse AW, Brunner S, Kyriatsoulis A, et al. Autoantibodies in experimental autoimmune hepatitis. J Hepatol 1992; 14:48-53
19. Lohse AW, Meyer zum Buschenfelde KH. Remission of experimental autoimmune hepatitis is associated with antigen-specific and non-specific immunosuppression. Clin Exp Immunol 1993; 94:163-167
20. Griffin JM, Gilbert KM, Lamps LW et al. CD4 activation and induction of autoimmune hepatitis following trichloroethylene mice. Toxicol Sci 2000; 57:345-352. treatment in MRL
21. Griffin JM, Gilbert KM, Pumford NR. Inhibition of CYP2E1 mice.?/?T-cell alterations in trichloroethylene-treated MRL reverses CD4 Toxicol Sci 2000; 54:384-389
22. Tyan ML. In vivo toxicity of concanavalin A. Proc Soc Exp Biol Med 1974; 146:1163-1165
23. Cao Q, Batey R, Pang G, et al. IL-6, IFNγ and TNFα production by liver-associated T cells and acute liver injury in rats administered concanavalin A. Immunol Cell Biol 1998; 76:542-549
24. Kimura K, Ando K, Ohnishi H, et al. Immunopathogenesis of hepatic fibrosis in chronic liver injury induced by repeatedly administered concanavalin A. Int Immunol 1999; 9:1491-1500
25. Tiegs G, Hentschel J, Wendel A. A T-cell dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992; 90:196-203
26. Trautwein C, Rakemann T, Brenner DA, et al. Concanavalin A-induced liver cell damage: Activation of intracellular pathways triggered by tumor necrosis factor in mice. Gastroenterology 1998; 114:1035-1045
27. Trautwein C, Rakemann T, Malek NP, et al. Concanavalin A-induced liver injury triggers hepatocyte proliferation. J Clin Invest 1998; 101: 1960-1969
28. Tiegs G, Küsters S, Künstle G. T cell-mediated experimental liver injury. In: Berg P, Lohse AW, Tiegs G, Wendel A, eds. Autoimmune Liver Disease, Proceedings of the International Falk Workshop. Lancaster, England: Kluwer Academic Publishers,1997: 32-42
29. Mizuhara H, O'Neill E, Seki N, et al. T cell activation-associated hepatic injury: Mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 1994; 179:1529-1537
30. Gantner F, Leist M, Lohse AW, et al. Concanavalin A-induced T cell-mediated hepatic injury in mice: The role of tumor necrosis factor. Hepatology 1995; 21:190-198
31. Küsters S, Tiegs G, Alexopoulou L, et al. In vivo evidence for a functional role of both TNF receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 1997; 27:2870-2875
32. Solorzano CC, Ksontini R, Pruitt JH, et al. Involvement of 26-kDa cell-associated TNFα in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J. Immunol 1997; 158:414-419
33. Bruck R, Shirin H, Hershkoviz R, et al. Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumor necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice. Gut 1997; 40:133-138
34. Ksontini R, Colagiovanni DB, Josephs MD, et al. Disparate roles for TNF-α and Fas ligand in concanavalin A-induced hepatitis. J Immunol 1998; 160:4082-1329
35. Faggioni R, Jones-Carson J, Reed DA, et al. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: Role of tumor necrosis factor α and IL-18. Proc Natl Acad Sci USA 2000; 97: 2367-2372
36. Küsters S, Gantner F, Künstle G, et al. Interferon- (plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 1996; 111:462-471
37. Mizuhara H, Uno M, Seki N, et al. Critical involvement of interferon γ in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis. Hepatology 1996; 23:1608-1615
38. Tagawa Y, Sekikawa K, Iwakura Y. Suppression of concanavalin A-induced hepatitis in IFN-γ(-/-) mice, but not in TNF-α(-/-) mice: Role for IFN-γ in activating apoptosis of hepatocytes. J Immunol 1997; 159:1418-1428
39. Nicoletti F, Zaccone P, Xiang M, et al. Essential pathogenetic role for interferon (IFN-)γ in concanavalin A-induced T cell-dependent hepatitis: Exacerbation by exogenous IFN-γ and prevention by IFN-γ receptor-immunoglobulin fusion protein. Cytokine 2000; 12: 315-323
40. Nicoletti F, Di Marco R, Zaccone P, et al. Murine concanavalin A-induced hepatitis is prevented by interleukin 12 (IL-12) antibody and exacerbated by exogenous IL-12 through an interferon-γ- dependent mechanism. Hepatology 2000; 32:728-733
41. Nakamura K, Okada M, Yoneda M, et al. Macrophage inflammatory protein-2 induced by TNF-α plays a pivotal role in concanavalin A-induced liver injury in mice. J Hepatol 2001; 35:217-224
42. Tagawa Y, Matthys P, Heremans H, et al. Bimodal role of endogenous interleukin-6 in concanavalin A-induced hepatitis in mice. J Leukoc Biol 2000; 67:90-96
43. Bozza M, Bliss JL, Maylor R, et al. Interleukin-11 reduces T-celldependent experimental liver injury in mice. Hepatology 1999; 30: 1441-1447
44. Louis H, Le Moine O, Peny MO, et al. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice. Hepatology 1997; 25:1382-1389
45. Di Marco R, Xiang M, Zaccone P, et al. Concanavalin A-induced hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency. Autoimmunity 1999; 31:75-83
46. Kato M, Ikeda N, Matsushita E, et al. Involvement of IL-10, an antiinflammatory cytokine in murine liver injury induced by concanavalin A. Hepatol Res 2001; 20:232-243
47. Okamoto T, Masuda Y, Kawasaki T, et al. Aminoguanidine prevents concanavalin A-induced hepatitis in mice. Eur J Pharmacol 2000; 396:125-130
48. Sass G, Koerber K, Bang R, et al. Inducible nitric oxide synthase is critical for immune-mediated liver injury in mice. J Clin Invest 2001; 107:439-447
49. Schümann J, Wolf D, Pahl A, et al. Importance of Kupffer cells for T cell-dependent liver injury in mice. Am J Pathol 2000; 157: 1671-1683
50. Künstle G, Hentze H, Germann P-G, et al. Concanavalin A hepatotoxicity in mice: Tumor necrosis factor-mediated organ failure independent of caspase-3-like protease activation. Hepatology 1999; 30:1241-1251
51. Streetz K, Fregien B, Plümpe J, et al. Dissection of the intracellular pathways in hepatocytes reveals a direct role of Jun Kinase and IRF-1 in Con A-induced liver failure. J Immunol 2001; 167:514-523
52. Toyabe S, Seki S, Iiai T, et al. Requirement of IL-4 and T cells for concanavalin A-induced hepatic injury in mice. J Immunol?liver NK1 1997; 159:1537-1542
53. Kaneko Y, Harada M, Kawano T, et al. Augmentation of Vα14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 2000; 191:105-114
54. Takeda K, Hayakawa Y, Van Kaer L, et al. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 2000; 97:5498-5503
55. Bendelac A, Rivera MN, Park SH, et al. Mouse CD1-specific NK1 T cells: Development, specificity, and function. Annu Rev Immunol 1997; 15:535-562
56. Satoh M, Kobayashi K, Ishii M, et al. Midzonal necrosis of the liver after concanavalin A-injection. Tohoku J Exp Med 1996; 180: 139-152
57. Gantner F, Küsters S, Wendel A, et al. Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors. J Pharmacol Exp Ther 1997; 280:53-60
58. Louis H, Le Moine A, Quertinmont E, et al. Repeated concanavalin A challenge in mice induces an interleukin 10-producing phenotype and liver fibrosis. Hepatology 2000; 31:381-390
59. Mizuhara H, Kuno M, Seki N, et al. Strain difference in the induction of T-cell activation-associated, interferon γ -dependent hepatic injury in mice. Hepatology 1998; 27:513-519
60. Egan HS, Reeder WJ, Ekstedt RD. Effect of concanavalin A in vivo in suppressing the antibody response in mice. J Immunol 1974; 112:63-69
61. Markowitz H, Person DA, Gitnick GL, et al. Immunosuppressive activity of concanavalin A. Science 1969; 163:476
62. Barth RF, Singla O. Differential effects of concanavalin A on T helper dependent and independent antibody responses. Cell Immunol 1973; 9:96-103
63. Biburger M, Erhardt A, Tiegs G. Hepatopathic immune-stimulatory drugs concanavalin A and α-galactosylceramide induce tolerance in murine models of immune-mediated hepatitis [abstract]. Hepatology 2004; 40 (Suppl):598A.
64. Shirin H, Bruck R, Aeed H, et al. Pentoxifylline prevents concanavalin A-induced hepatitis by reducing tumor necrosis factor-α levels and inhibiting adhesion of T lymphocytes to extracellular matrix. J Hepatol 1998; 29:60-67
65. Tiegs G, Küsters S, Künstle G, et al. Ebselen protects mice against T cell-dependent, TNF-mediated apoptotic liver injury. J Pharmacol Exp Ther 1998; 287:1098-1104
66. Bahr GM, Pouillart PR, Chedid LA. Enhancement in vivo of the antiinflammatory and antitumor activities of type I interferon by association with the synthetic immunomodulator murabutide. J Interferon Cytokine Res 1996; 16:297-306
67. Aurisicchio L, Delmastro P, Salucci V, et al. Liver-specific α 2 interferon gene expression results in protection from induced hepatitis. J Virol 2000; 74:4816-4823
68. Hershkoviz R, Bruck R, Aeed H, et al. Treatment of concanavalin A-induced hepatitis in mice with low molecular weight heparin. J Hepatol 1999; 31:834-840
69. Santucci L, Fiorucci S, Cammilleri F, et al. Galectin-1 exerts immunomodulatory and protective effects on concanavalin A-induced hepatitis in mice. Hepatology 2000; 31:399-406
70. Kuzuhara H, Nishiyama S, Minowa N, et al. Protective effects of soyasapogenol A on liver injury mediated by immune response in a concanavalin A-induced hepatitis model. Eur J Pharmacol 2000; 391:175-181
71. Yamashiki M, Mase A, Arai I, Huang, et al. Effects of the Japanese herbal medicine 'Inchinko-to' (TJ-135) on concanavalin A-induced hepatitis in mice. Clin Sci (Colch) 2000; 99:421-431
72. Fiorucci S, Santucci L, Antonelli E, et al. NO-aspirin protects from T cell-mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines. Gastroenterology 2000; 118: 404-421
73. Fiorucci S, Mencarelli A, Palazzetti B, et al. An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity. Proc Natl Acad Sci USA 2001; 98: 2652-2657
74. Wolf D, Schümann J, Koerber K, et al. Low molecular weight hyaluronic acid induces nuclear factor-B-dependent resistance against tumor necrosis factor-α-mediated liver injury in mice. Hepatology 2001; 34:535-547
75. Kobayashi E, Motoki K, Uchida T, et al. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995; 7:529-534
76. Osman Y, Kawamura T, Naito T, et al. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur J Immunol 2000; 30: 1919-1928
77. Nakagawa R, Nagafune I, Tazunoki Y, et al. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol 2001; 166: 6578-6584
78. Biburger M, Tiegs G. Alpha-galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells. J Immunol 2005; 175:1540-1550
79. Inui T, Nakashima H, Habu Y, et al. Neutralization of tumor necrosis factor abrogates hepatic failure induced by alpha-galactosylceramide without attenuating its antitumor effect in aged mice. J Hepatol 2005; 43:670-678
80. Inui T, Nakagawa R, Ohkura S, et al. Age-associated T?augmentation of the synthetic ligand-mediated function of mouse NK1.1 ag cells: Their cytokine production and hepatotoxicity in vivo and in vitro. J Immunol 2002; 169:6127-6132
81. Zeng D, Liu Y, Sidobre S, et al. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. Clin Invest 2003; 112:1211-1222
82. Uldrich AP, Crowe NY, Kyparissoudis K, et al. NKT cell stimulation with glycolipid antigen in vivo: Costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol 2005; 175:3092-3101
83. Biburger M, Tiegs G. A single pretreatment with α- galactosylceramide causes activation-induced nonresponsiveness of murine NKT cells and results in tolerance against NKT-mediated liver injury [abstract]. Immunobiology 2005; 210:N.1
84. Lapierre P, Djilali-Saiah I, Vitozzi S, et al. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology 2004; 39:1066-1074
85. Djilali-Saiah I, Lapierre P, Vittozi S, et al. DNA vaccination breaks tolerance for a neo-self antigen in liver: A transgenic murine model of autoimmune hepatitis. J Immunol 2002; 169:4889-4896
86. Lapierre P, Beland K, Djilali-Saiah I, et al. Type 2 autoimmune hepatitis murine model: The influence of genetic background in disease development. J Autoimmun 2006; 26:82-89
87. Bowen DG, Warren A, Davis T, et al. Cytokine-dependent bystander hepatitis due to intrahepatic murine CD8 T-cell activation by bone marrow-derived cells. Gastroenterology 2002; 123: 1252-1264
88. Voehringer D, Blaser C, Grawitz AB, et al. Break of T cell ignorance to a viral antigen in the liver induces hepatitis. J Immunol 2000; 165:2415-2422
89. Watanabe Y, Kawakami H, Kawamoto H, et al. Effect of neonatal thymectomy on experimental autoimmune hepatitis in mice. Clin Exp Immunol 1987; 67:105-113
90. Yoshida Y, Myozaki M, Kuroda E, et al. Cytotoxic effect of an antiliver monoclonal autoantibody obtained after neonatal thymectomy in mice. J Autoimmun 2001; 16:373-382
91. Notarangelo LD, Mazza C, Forino C, et al. AIRE and immunological tolerance: Insights from the study of autoimmune polyendocrinopathy candidiasis and ectodermal dystrophy. Curr Opin Allergy Clin Immunol 2004; 4:491-496
92. Su MA, Anderson MS. Aire: An update. Curr Opin Immunol 2004; 16:746-752
93. Rizzi M, Ferrera F, Filaci G, et al. Disruption of immunological tolerance: Role of AIRE gene in autoimmunity. Autoimmun Rev 2006; 5:145-147
94. Jiang W, Anderson MS, Bronson R, et al. Modifier loci condition autoimmunity provoked by Aire deficiency. J Exp Med 2005; 202: 805-815
95. Chen Z, Benoist C, Mathis D. How defects in central tolerance impinge on a deficiency in regulatory T cells. Proc Natl Acad Sci USA 2005; 102:14735-14740
96. Gorham JD, Lin JT, Sung JL, et al. Genetic regulation of autoimmune disease: BALB/c background TGF-beta 1-deficient mice develop necroinflammatory IFN-gamma-dependent hepatitis. J Immunol 2001; 166:6413-6422
97. Rudner LA, Lin JT, Park IK, et al. Necroinflammatory T?liver disease in BALB/c background, TGF-beta 1-deficient mice requires CD4 cells. J Immunol 2003; 170:4785-4792
98. Robinson RT, French MA, Kitzmiller TJ, et al. T-cell receptor repertoire prevents immune pathology in?Restriction of the CD4 TGF-beta1 knockout mice. Lab Invest 2006; 86:815-828
99. Kobashi H, Yamamoto K, Yoshioka T, et al. Nonsuppurative cholangitis is induced in neonatally thymectomized mice: A possible animal model for primary biliary cirrhosis. Hepatology 1994; 19: 1424-1430
100. Ueno Y, Phillips JO, Ludwig J, et al. Development and characterization of a rodent model of immune-mediated cholangitis. Proc Natl Acad Sci USA 1996; 93:216-220
101. Ueno Y, Ishii M, Takahashi S, et al. Different susceptibility of mice to immune-mediated cholangitis induced by immunization with carbonic anhydrase II. Lab Invest 1998; 78:629-637
102. Jones DE. Autoantigens in primary biliary cirrhosis. J Clin Pathol 2000; 53:813-821
103. Krams SM, Surh CD, Coppel RL, et al. Immunization of experimental animals with dihydrolipoamide acetyltransferase, as a purified recombinant polypeptide, generates mitochondrial antibodies but not primary biliary cirrhosis. Hepatology 1989; 9:411-416
104. Jones DE, Palmer JM, Bennett K, et al. Investigation of a mechanism for accelerated breakdown of immune-tolerance to the primary biliary cirrhosis-associated autoantigen, pyruvate dehydrogenase complex. Lab Invest 2002; 82:211-219
105. Robe AJ, Kirby JA, Jones DE, et al. A key role for autoreactive B cells in the breakdown of T-cell tolerance to pyruvate dehydrogenase complex in the mouse. Hepatology 2005; 41:1106-1112
106. Palmer JM, Robe AJ, Burt AD, et al. Covalent modification as a mechanism for the breakdown of immune tolerance to pyruvate dehydrogenase complex in the mouse. Hepatology 2004; 39: 1583-1592
107. Woolf GM, Vierling JM. Disappearing intrahepatic bile ducts: The syndromes and their mechanisms. Sem in Liver Dis 1993; 13:261-275
108. Fickert P, Fuchsbichler A, Wagner M, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004; 127:261-274
109. Dikengil A, Siskind BN, Morse SS, et al. Sclerosing cholangitis from intraarterial floxuridine. J Clin Gastroenterol 1986; 8:690-693
110. Doppman JL, Girton ME. Bile duct scarring following ethanol embolization of the hepatic artery: An experimental study in monkeys. Radiology 1984; 152:621-626
111. Orth T, Neurath M, Schirmacher P, et al. Anti-neutrophil cytoplasmic antibodies in a rat model of trinitrobenzenesulphonic acid-induced liver injury. Eur J Clin Invest 1999; 29:929-939
112. Mourelle M, Salas A, Vilaseca J, et al. Induction of chronic cholangitis in the rat by trinitrobenzenesulfonic acid. J Hepatol 1995; 22: 219-225
113. Orth T, Neurath M, Schirmacher P, Galle et al. A novel rat model of chronic fibrosing cholangitis induced by local administration of a hapten reagent into the dilated bile duct is associated with increased TNF-alpha production and autoantibodies. J Hepatol 2000; 33: 862-872
114. Goetz M, Lehr HA, Neurath MF, et al. Long-term evaluation of a rat model of chronic cholangitis resembling human primary sclerosing cholangitis. Scand J Immunol 2003; 58:533-540
115. Tjandra K, Sharkey KA, Swain MG. Progressive development of a Th1-type hepatic cytokine profile in rats with experimental cholangitis. Hepatology 2000; 31:280-290
116. Kotzampassi K, Eleftheriadis E, Tzioufa V, et al. Formalin-induced experimental sclerosing cholangitis in the rat. Histol Histopathol 1989; 4:251-255
117. Houry S, Languille O, Huguier M, et al. Sclerosing cholangitis induced by formaldehyde solution injected into the biliary tree of rats. Arch Surg 1990; 125:1059-1061
118. Tjandra K, Le T, Swain MG. Glucocorticoid receptors are downregulated in hepatic T lymphocytes in rats with experimental cholangitis. Gut 2003; 52:1363-1370
119. Tjandra K, Le T, Swain MG. Experimental colitis attenuates development of toxin-induced cholangitis in rats. Dig Dis Sci 2002; 47:1216-1223
120. Lichtman SN, Sartor RB, Keku J, et al. Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 1990; 98:414-423
121. Lichtman SN, Keku J, Clark RL, et al. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 1991; 13:766-772
122. Lichtman SN, Keku J, Schwab JH, et al. Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology 1991; 100: 513-519
123. Lichtman SN, Okoruwa EE, Keku J, et al. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest 1992; 90:1313-1322
124. Numata Y, Tazuma S, Nishioka T, et al. Immune response in mouse experimental cholangitis associated with colitis induced by dextran sulfate sodium. J Gastroenterol Hepatol 2004; 19:910-915
125. Numata Y, Tazuma S, Ueno Y, et al. Therapeutic effect of repeated natural killer T cell stimulation in mouse cholangitis complicated by colitis. Dig Dis Sci 2005; 50:1844-1851